Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial
| Autor: | Álvaro Sánchez Barrueco, María Victoria Mateos-Moreno, Yolanda Martínez-Beneyto, Elisa García-Vázquez, Alfonso Campos González, Javier Zapardiel Ferrero, Abel Bogoya Castaño, Ignacio Alcalá Rueda, José Miguel Villacampa Aubá, Carlos Cenjor Español, Laura Moreno-Parrado, Verónica Ausina-Márquez, Sandra García-Esteban, Alejandro Artacho, F. Xavier López-Labrador, Alex Mira, María D. Ferrer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Emerging Microbes and Infections, Vol 11, Iss 1, Pp 1833-1842 (2022) |
| Druh dokumentu: | article |
| ISSN: | 22221751 2222-1751 |
| DOI: | 10.1080/22221751.2022.2098059 |
| Popis: | Background: In vitro studies have shown that several oral antiseptics have virucidal activity against SARS-CoV-2. Thus, mouthwashes have been proposed as an easy to implement strategy to reduce viral transmission. However, there are no data measuring SARS-CoV-2 viability after mouthwashes in vivo. Methods: In this randomized double-blind, five-parallel-group, placebo-controlled clinical trial, SARS-CoV-2 salivary viral load (by quantitative PCR) and its infectious capacity (incubating saliva in cell cultures) have been evaluated before and after four different antiseptic mouthwashes and placebo in 54 COVID-19 patients. Results: Contrary to in vitro evidence, salivary viral load was not affected by any of the four tested mouthwashes. Viral culture indicated that cetylpyridinium chloride (CPC) significantly reduced viral infectivity, but only at 1-hour post-mouthwash. Conclusion: These results indicate that some of the mouthwashes currently used to reduce viral infectivity are not efficient in vivo and, furthermore, that this effect is not immediate, generating a false sense of security.Trial registration: ClinicalTrials.gov identifier: NCT04707742.. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|